Intravitreal Triamcinolone Prior to Laser Treatment of Diabetic Macular Edema 24-Month Results of a Randomized Controlled Trial

Grants

Funding Acknowledgements

The author(s) have made the following disclosure(s): Mark C. Gillies - Patents - Formulation of triamcinolone for ocular use and its use for the treatment of retinal neovascularization, but not macular edema; Financial support - Allergan; Honoraria - Allergan, Novartis, and PfizerSupported by grants from the National Health and Medical Research Council, Canberra, Australia, and the Sydney Eye Hospital Foundation, Sydney, Australia. The study was investigator initiated and unsupported by the pharmaceutical industry.